Patents
Literature
3548 results about "Target protein" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Target proteins are functional biomolecules that are addressed and controlled by biologically active compounds. They are used in the processes of transduction, transformation and conjugation. The identification of target proteins, the investigation of signal transduction processes and the understanding of their interaction with ligands are key elements of modern biomedical research. Since the interaction with target proteins is the molecular origin of most drugs, their particular importance for molecular biology, molecular pharmacy and pharmaceutical sciences is obvious. Target proteins control the action and the kinetic behavior of drugs within the organism. The elucidation of structure, conformational signaling and catalytic properties of particular target proteins facilitates a rational design of drugs and biotechnological processes. Known as biologicals, target proteins can also be drugs by themselves when their modification and formulation is emphasized within the pharmaceutical sciences. Finally, target protein - inducer interactions can be exploited for biomolecular transcription regulating systems in order to control for example gene therapeutic approaches.
Protac compounds binding KEAP1 ubiquitin ligase for targeted protein degradation
PCT designated stage expiredWO2025083472A2Organic active ingredientsAntibody ingredientsKEAP1Protein degradation
The present disclosure relates to methods of co-administering PROTAC (proteolysis targeting chimera) compounds that can promote ubiquitination and degradation of a target protein. The present disclosure also relates to antibody drug conjugates of PROTAC compounds Also disclosed herein are pharmaceutical compositions that can include a compound of Formula (V), the use and preparation thereof.
Owner:SEED THERAPEUTICS US INC +1
Compound targeting protein modulator and use thereof
PCT designated stage expiredWO2025103476A1Organic active ingredientsOrganic chemistryProtein targetPharmacology
Owner:SHANGHAI PHARMACEUTICALS HOLDING CO LTD
Targeting RAS-Raf protein interaction stapled peptide and application thereof in antitumor drugs
PendingCN120040551APeptide/protein ingredientsPeptide preparation methodsProtein targetStapled peptide
The invention relates to the field of biological medicine, in particular to a stapled peptide targeting RAS-Raf protein interaction and application of the stapled peptide, the stapled peptide is obtained in the mode that Ac-SLHDCLMKALKVR-NH2 and Ac-SLHDCLMKALKVRGL-NH2 serve as peptide chain templates, amino acid at the i site and amino acid at the (i + 4) site are replaced with S5 and cyclized, and the nitrogen terminal is further modified with stearic acid. The stapled peptide can effectively inhibit proliferation and migration of tumor cells; the serum stability is high, and meanwhile, the cell transmembrane capability is excellent, so that target protein in cells can be better targeted, and the biological function of the target protein can be exerted. Therefore, the alphaH helical conformation of the RBD of the RAF can be stabilized through the stapled peptide and a nitrogen-terminal fatty acid modification strategy, the membrane permeability and stability of the RAF are improved, the binding force of the RAF and RAS is further improved, and proliferation and migration of various tumor cells are inhibited.
Owner:THE NAVAL MEDICAL UNIV OF PLA
Method for bioprotac design
PCT designated stage expiredWO2025125630A1Antibody mimetics/scaffoldsFusion with degradation motifProtein targetEngineering
Owner:MEDIMMUNE LTD
Bifunctional compound and use thereof
The present invention relates to a bifunctional Kras modulator (K-T or K-L-T) and the use thereof, wherein K represents a targeting group and is a modulator of a Kras protein (target protein), T is a ligand group of an E3 ubiquitin ligase, and L is a divalent linking group that chemically links the targeting group (K) to the ligand group (T). The bifunctional modulator or compound and a composition thereof disclosed in the present invention have pharmacological activity of degrading or inhibiting the target protein, and can be used for treating, inhibiting or preventing Kras-related diseases or disorders.
Owner:RISEN (SUZHOU) PHARMA TECH CO LTD +1
Drug and target interaction prediction method based on multi-scale convolution feature fusion
The invention discloses a drug and target interaction prediction method based on multi-scale convolution feature fusion, which comprises the following steps: acquiring drug molecule data, target protein data and drug and target interaction data, constructing a drug molecule map according to the drug molecule data, and coding a target protein sequence according to the target protein data; inputting the drug molecular map into a model, and obtaining drug features through a multi-scale map convolutional network and a dynamic gating attention mechanism; inputting a target protein sequence into the model, and obtaining target features through hierarchical cavity convolution and a bidirectional gating cycle unit; through multi-head cross attention, the drug features are aligned with the target features, local and global cross-modal fusion is carried out, and drug target fusion features are obtained; based on the drug target fusion features, outputting a drug and target interaction prediction probability; and training the model according to the drug and target interaction data and the prediction probability, and applying the trained model to drug and target interaction prediction.
Owner:GUANGDONG UNIV OF EDUCATION
Drug molecule screening and optimizing method based on artificial intelligence prediction
The invention relates to the technical field of computer-aided drug design, in particular to a drug molecule screening and optimizing method based on artificial intelligence prediction, which comprises the following steps: S1, obtaining a dynamic protein conformation set and molecular multi-dimensional characterization: obtaining a dynamic conformation set of a target protein and a physicochemical property spatial distribution diagram of a binding pocket of the dynamic conformation set, a two-dimensional molecular map topological structure and three-dimensional conformation coordinates of the drug molecules are obtained; s2, multi-modal fusion prediction is carried out; s3, generating interpretable optimization guidance; and S4, automatic iterative optimization: performing batch prediction and screening on the new candidate molecular structure, taking the screened optimal molecule as a new starting point, repeatedly executing the interpretability optimization guidance generation step and the step until an iteration termination condition is met, and outputting a final optimized molecule list. Through the multi-modal fusion deep learning model, the interaction strength of the drug molecules and the target protein can be quickly and accurately predicted, and the screening efficiency of the drug molecules is greatly improved.
Owner:WENZHOU MEDICAL UNIV
Protein targeted degradation system capable of being regulated and controlled in programmable mode, construction and application of protein targeted degradation system
ActiveCN119495366AEfficient degradationPrecise regulation of degradationProteomicsGenomicsProtein targetDanoprevir
The invention discloses a modified Trim 21 (delta Trim 21)-based target protein degradation control system, which takes a modified protein delta Trim 21 degradation system as a basis, takes blue light, abscisic acid, Danoprevir and / or MK-5172 as inductors, controls the combination of target protein and delta Trim 21 by introducing and modifying a controllable protein dimerization system on the basis of the modified protein delta Trim 21 degradation system, and improves the target protein degradation control system. The protein targeted degradation capable of being modularly regulated and controlled is carried out. Two regulation and control modules, namely a target protein recognition module and a degradation module based on E3 ubiquitinase, are constructed by splitting and recombining a controllable protein dimerization system and a delta Trim 21 structural domain. The invention also discloses a degradation device comprising the system. The invention also discloses a method for accurately regulating endogenous proteins (degradation of proteins related to tumorigenesis) by using the programmable regulation type modular protein degradation device, so as to achieve the effect of specifically killing tumors. The invention also provides a eukaryotic expression vector and a regulation method of the programmable regulation type protein targeted degradation device.
Owner:EAST CHINA NORMAL UNIV
Protein purification method
PendingCN119350505AImmunoglobulins against blood coagulation factorsBacteriaProtein targetProtein purification
The present invention relates to a method for the production and purification of a protein of interest, and more particularly, the present invention relates to a fusion protein comprising: a self-aggregating peptide, a linker peptide comprising an amino acid sequence selected from an elastin-like polypeptide (ELP) or a protease propeptide (ProP) and the spacer comprising a cleavage site, and a protein portion of interest, and a method for column-free one-step purification of a target protein by expressing the fusion protein.
Owner:GUANGZHOU NOVI SYNTHETIC BIOTECHNOLOGY CO LTD
Substituted piperidinediones for targeted protein degradation
PCT designated stage expiredWO2025024521A1Organic active ingredientsAntipyreticInterstitial lung diseasePericarditis
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg. anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.
Owner:MONTE ROSA THERAPEUTICS AG
Mutant protein screening method and device and related equipment
ActiveCN119296640AImprove filtering effectShorten the test cycleBiostatisticsProteomicsMutated proteinProtein target
The invention discloses a mutant protein screening method and device and related equipment thereof, and relates to the technical field of material determination and analysis. The method comprises the following steps: respectively carrying out simulated single mutation on a plurality of amino acid sites in a protein sequence of a target protein to obtain a plurality of simulated mutant proteins, and determining adaptability evaluation values F of the plurality of simulated mutant proteins based on a target protein language model; determining structural stability values S of the plurality of simulated mutant proteins based on a protein folding energy calculation tool; performing normalization processing on the adaptability evaluation value F and the structural stability value S, and performing single-index sorting and comprehensive-index sorting on normalization processing results; and screening the plurality of simulated mutant proteins according to the target screening number, the single index sorting result and the comprehensive index sorting result to obtain a target mutant protein. According to the method, the protein design transformation difficulty can be reduced, the mutant protein screening effect is improved, the calculation amount required by protein transformation and screening is reduced, and the consumption cost is reduced.
Owner:CIXI INST OF BIOMEDICAL ENG NINGBO INST OF IND TECH CHINESE ACAD OF SCI NINGBO +1
Preparation method of electrochemical biosensor based on PLL-coated VPAu modified nuclear track membrane
ActiveCN119165026AMaterial nanotechnologyMaterial analysis by electric/magnetic meansElectrochemical biosensorProtein target
The invention provides a preparation method of an electrochemical biosensor based on a PLL-coated VPAu modified nuclear track membrane, and belongs to the field of electrochemical biosensing analysis. The electrochemical biosensor for detecting troponin is constructed by adsorbing a PLL (at) VPAu composite nanomaterial synthesized by an ultrasonic liquid phase assisted method into a nuclear track membrane pore channel through electrostatic interaction and connecting a specific recognition molecule of a target to the surface of the pore channel modified by the PLL (at) VPAu by utilizing a bonding reaction mechanism. After a target object is captured by the recognition molecules connected to the nuclear track membrane, the effective aperture of the nuclear track membrane nanopores is reduced, and the electrochemical workstation can convert the biological behavior into an electric signal, so that high-sensitivity and rapid detection of the target protein is realized. The method has very important theoretical and practical significance in the field of medical diagnosis, and a new direction is provided for application of the nuclear track membrane in the field of analysis and detection.
Owner:UNION MEDICAL & PHARM TECH TIANJIN GRP LTD
Targeting BamA antibacterial peptide as well as preparation method and application thereof
The invention discloses a BamA-targeting antibacterial peptide as well as a preparation method and application thereof, and is characterized in that amino acids in a sequence are all D-type amino acids, and the amino acid sequence is as follows: w-r-r-w-r-r-p-w-k-r (dTrp-dArg-dArg-dTrp-dArg-dArg-dPro-dTrp-dLys-dArg). The antibacterial peptide provided by the invention has good antibacterial activity, can be synthesized by adopting an Fmoc solid-phase chemical method, is low in preparation difficulty, and has high affinity with target protein BamA.
Owner:CHONGQING UNIV OF TECH +1
Protein purification method
The invention relates to the technical field of protein purification, in particular to a biological method for purifying fusion protein through two different affinity tags. Two affinity purification tags and a dissolution promoting tag are perfectly combined, so that soluble expression of recombinant protein is ensured, high-purity target protein can be obtained through a two-step mild and efficient affinity purification process, the function and activity of the protein are ensured, a complex'capture-medium purification-fine purification 'multi-step purification process is avoided, and the method is suitable for industrial production. The purification process is shortened, the purification time is shortened, the purification efficiency is improved, and the method can be used for production and purification of functional proteins.
Owner:CHANGZHOU SMART LIFESCI CO LTD
Methods and reagents for analyzing protein-protein interfaces
The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and / or presenter proteins are intracellular proteins. In some embodiments, the target and / or presenter proteins are mammalian proteins.
Owner:REVOLUTION MEDICINES INC
Traditional Chinese medicine multi-target interaction prediction method based on Transform architecture
PendingCN119479785AImprove training efficiencyflexible structureBiostatisticsNeural learning methodsNew medicationsProtein target
The invention discloses a traditional Chinese medicine multi-target interaction prediction method based on a Transform architecture. The method comprises the following steps: creating an interaction label of a medicine and a target; respectively carrying out feature extraction on the traditional Chinese medicine component data and the target protein data; fusing the traditional Chinese medicine component feature vector and the target feature vector through a cross attention mechanism; creating a data set by using the feature vector F and an interaction label of the drug and the target; the method comprises the following steps of: constructing and training a Transform encoder; inputting a to-be-detected medicine-target data set into the trained Transformer encoder, outputting a probability value of interaction between each target and the traditional Chinese medicine component, and when the probability value of interaction between the traditional Chinese medicine component and the target is greater than a preset threshold value, determining that interaction exists; the invention provides an efficient and accurate traditional Chinese medicine multi-target interaction prediction means, and is beneficial to acceleration of traditional Chinese medicine research and new medicine development processes.
Owner:CHINA PHARM UNIV
Drug target prediction method based on 3D structure and multi-level attention mechanism
The invention provides a drug target prediction method based on a 3D structure and a multilevel attention mechanism, and belongs to the technical field of drug target prediction. The technical problem to be solved is to provide a drug target prediction method based on a 3D structure and a multi-level attention mechanism. According to the technical scheme, the method comprises the following steps: collecting data information of an interaction tag among a related drug, a target sequence and a drug target protein, and processing and extracting SMILES character string characteristics of the drug; learning the numeralized protein amino acid sequence by using a convolutional neural network, completing feature coding of a target spot on the sequence through multi-layer convolution and pooling operation, and extracting target spot sequence feature data; a PDB file is read and modeled into a pocket graph, feature calculation is carried out on the pocket graph, a final protein structure representation code is generated, and structural feature data of target protein is extracted by modeling the PDB file; the method is applied to drug target prediction.
Owner:TAIYUAN UNIVERSITY OF TECHNOLOGY
Pan-KRAS targeted protein degradation agent, preparation method therefor, and use thereof
The present invention provides a class of small molecule compounds for targeted degradation of a pan-KRAS protein, a preparation method therefor, and use thereof as a therapeutic agent for preventing and / or treating cancer. The compound of the present invention can effectively degrade and / or inhibit the pan-KRAS protein in cells, and can be used for preparing a drug for treating and / or preventing related diseases or disorders caused by pan-KRAS mediation.
Owner:LEADING PHARMACEUTICAL (SHAOXING) CO LTD
Artificial intelligence-based pharmaceutical knowledge graph construction method and system
The invention relates to the technical field of pharmaceutical knowledge maps, in particular to a pharmaceutical knowledge map construction method and system based on artificial intelligence, and the method comprises the following steps: querying and collecting a molecular structure of a drug and a corresponding target protein sequence through a database, and carrying out the numerical coding of the molecular structure data of the drug, molecular fingerprints and protein structural domain features are extracted, and a drug and protein feature set is formed by combining drug chemical attributes and protein sequence features. According to the invention, through accurate analysis of the molecular structure of the drug and the target protein sequence thereof, the innovative scheme significantly enhances the understanding of the interaction of the drug and the protein, so that researchers can directly extract key features from data and monitor the dynamic change of the drug effect, thereby not only accelerating the development process of the drug, but also improving the development efficiency of the drug. By dynamically tracking the interaction between the side effect of the medicine and the pathological characteristics, the scheme provides powerful data support for personalized medical treatment.
Owner:CENT SOUTH UNIV +1
Recombinant collagen based on engineering bacterium expression and preparation method thereof
The invention belongs to the technical field of genetic engineering, and particularly relates to recombinant collagen based on engineering bacterium expression and a preparation method thereof, and the recombinant collagen is formed by connecting repetitive units derived from human III type collagen in series for three times; the invention also discloses a base sequence of the coding gene of the recombinant collagen, efficient expression and accurate folding of target protein are realized through genetic modification of engineering bacteria, a light-operated dynamic folding process and an orthogonal purification strategy, and cascade purification of a His6-SUMO tag and an intein-CBD module is utilized to obtain the recombinant collagen. The product purity and the native conformation retention rate are remarkably improved, and the technical problems that hydroxyproline depends on exogenous addition, the folding controllability is poor and the purification efficiency is low in a traditional process are solved.
Owner:HUAFAN BIOTECHNOLOGY (GANSU) CO LTD
Drug target binding affinity prediction method based on multi-modal data fusion enhancement
The invention provides a drug target binding affinity prediction method based on multi-modal data fusion. The method comprises the following steps: firstly, extracting sequence feature information of drug SMILES and target FASTA, then constructing an affinity graph, modeling drug molecules and target protein molecules into an undirected graph, and extracting molecular-level features of atoms, bonds, residues and contact. And fusing the hierarchical graph structure information of the affinity graph and the molecular graph to obtain the graph structure feature representation of the drug-target spot. The sequence feature information and the graph structure feature representation are further fused by using intramolecular and intermolecular attention fusion mechanisms. And finally, performing affinity prediction by using the fused features, and outputting a drug-target binding affinity score. According to the method, sequence and structural information are effectively fused, the accuracy of drug target affinity prediction is improved, and the problems of insufficient information fusion and insufficient structural information utilization in an existing method are solved.
Owner:WUHAN UNIV OF SCI & TECH
Combined element for screening aptamer and use thereof, and high-throughput screening method for aptamer
PCT designated stage expiredWO2025010661A1Nucleotide librariesMicrobiological testing/measurementAptamerGenomics
A high-throughput screening method for an aptamer, and a use. An implementation route is divided into three parts, a first part is construction of a library of a pre-enriched aptamer and sequencing same, a second part is generation of an aptamer cluster on a slide, and a third part is combination of a target protein and the aptamer cluster. Provided is a method for high-throughput rapid detection of an aptamer. The method has the beneficial effects: sequencing time, sequence synthesis and affinity re-verification time are saved, the affinity verification costs are greatly saved, rapid screening of aptamers can be promoted, and the actual use of aptamers is promoted along with the increase in the types and numbers of aptamers. The existing platform BGISEQ 500 of Beijing Genomics Institute can be used to grow an aptamer cluster on a chip by using DNB as a template, and the use of sequencers is expanded by integrating sequencing, sequence synthesis and affinity identification.
Owner:SHENZHEN HUADA GENE INST
Lead compound discovery method based on large language model
The invention is applicable to the technical field of drug research and development, and provides a lead compound discovery method based on a large language model, which comprises the following steps: determining a target spot and constructing an initial compound library; generating fragments and forming an initial fragment library; calculating the frequency of occurrence of the fragments and the affinity contribution degree of the fragments to the target protein, and updating the fragment library; fragment sampling weight calculation and candidate fragment selection; the large language model generates molecules according to the candidate fragments; evaluating the quality of the generated molecules and updating the molecule library; and repeating the cycle until a preset iteration round number is reached. A fragment-based drug design method is combined with the large language model, rich domain knowledge of the large language model is used for replacing human experts to guide drug design, fragments are used as prompts to stimulate the internal potential of the large language model, the advantages of the two methods complement each other, exploration of the whole chemical space is completed, and the drug design efficiency is improved. The lead compound reaching the human expert level is designed in actual use, and a new technical means is provided for drug research and development.
Owner:JILIN UNIVERSITY
Recombinant vector for expressing LPL, recombinant bacterium and LPL production method
The invention provides a recombinant vector for expressing LPL, a recombinant bacterium and an LPL production method, and belongs to the technical field of gene engineering. The invention provides a recombinant expression vector of Pseudomonas aeruginosa lipoprotein lipase LPL, wherein an LPL coding gene is derived from Pseudomonas aeruginosa. The recombinant expression vector is introduced into a pseudomonas aeruginosa PAO1 cell, an expression strain is successfully constructed, the expression quantity of target protein is improved, efficient expression of LPL in PAO1 is achieved, and the produced LPL is high in enzyme activity and wider in application range.
Owner:JIAPU TIANCHENG (SHANGHAI) BIOTECHNOLOGY CO LTD
Lymphocyte targeted lentiviral vectors
ActiveUS12312593B2Polypeptide with localisation/targeting motifSsRNA viruses negative-senseHeterologousProtein target
Provided herein are lentiviral vectors comprising a mutated, heterologous envelope protein, a targeting protein, and at least one transgene for delivery to and expression by a cell characterized by the targeting protein. Also provided are methods and materials for producing the lentiviral vectors described herein, methods for transducing target cells, and cells transduced by lentiviral vectors according to the present disclosure.
Owner:KELONIA THERAPEUTICS INC
Recombinant IV type collagen as well as preparation method and application thereof
ActiveCN119286901Agood biocompatibilityImprove biological activityCosmetic preparationsPeptide/protein ingredientsInflammatory factorsProtein target
The invention provides recombinant IV-type collagen as well as a preparation method and application thereof, and relates to the technical field of biochemical engineering. The preparation method of the recombinant IV-type collagen comprises the following steps: obtaining a codon from amino acid of the recombinant IV-type collagen, further obtaining a target gene, and synthesizing the target gene onto an expression vector to obtain a plasmid; transferring the plasmid into an expression host, and screening a positive transformant to obtain an expression strain; and culturing the expression strain, and expressing the target protein to obtain the crude recombinant IV-type collagen. The high-purity recombinant IV-type collagen is prepared through a genetic engineering technology, and the recombinant IV-type collagen can significantly down-regulate inflammatory factors and reduce inflammation; heat injury can be reduced by up-regulating heat shock protein; after heat injury, the recombinant IV-type collagen can obviously lower metal matrix protease of heat injury cells, and also can obviously promote gene expression of type I collagen and type III collagen, improve skin elasticity and moisture content and delay skin aging.
Owner:XIAN GIANT BIOGENE TECH CO LTD +1
Molecular generation method and device, storage medium, equipment and program product
The invention discloses a molecule generation method and device, a storage medium, equipment and a program product, which are applied to a molecule generation scene. The method comprises the following steps: obtaining known modal protein information corresponding to a target protein; performing feature processing on the known modal protein information based on a feature processing module of the trained multi-modal language model to obtain multi-modal standardized features corresponding to the target protein; based on a molecule generation module of the trained multi-modal language model, performing molecule generation processing on the multi-modal standardized features to obtain a target molecule aiming at the target protein; the trained multi-modal language model is obtained by training based on a multi-modal data set, and the multi-modal data set comprises a sequence modal sample, a structure modal sample and a pocket modal sample of a sample protein corresponding to a sample molecule. According to the method, high-quality drug molecules can be generated under the condition that the target protein lacks certain modal information, and the drug design efficiency is improved.
Owner:TENCENT TECHNOLOGY (SHENZHEN) CO LTD +1
Targeting exosome capable of delivering nucleic acid drugs and preparation method thereof
PendingCN119193497AImprove loading efficiencyprecision therapyFusion with RNA-binding domainFusion with DNA-binding domainProtein targetProtein molecules
The invention relates to the technical field of biological medicine, and provides a targeting exosome capable of delivering nucleic acid drugs and a preparation method of the targeting exosome. The exosome comprises a fusion polypeptide, the fusion polypeptide comprises a targeting protein molecule, an exosome transmembrane protein and a nucleic acid binding domain, and the exosome can load a nucleic acid molecule through binding of the nucleic acid binding domain. According to the invention, engineering modification is carried out on the exosome, so that nucleic acid molecules can be efficiently loaded into the exosome, and meanwhile, the exosome is endowed with the capability of targeting to specific target cells, tissues and organs.
Owner:P S K BIOSCIENCE CO LTD
Drug target prediction method and device, electronic equipment and storage medium
The invention discloses a drug target prediction method and device, electronic equipment and a storage medium. The method comprises the following steps: performing dynamic gating fusion on graph structure features and sequence features of a target drug to obtain drug features; performing dynamic feature enhancement on the digitized sequence of the target protein, and further obtaining protein features through context sensing optimization; obtaining a target affinity score of the target drug and the target protein by using a prediction model based on the drug characteristics and the protein characteristics; wherein the prediction model is obtained through feature representation training marked with actual affinity scores on the basis of a neural network. According to the method, the prediction precision of drug target interaction is improved through deep fusion of drug multi-modal features and protein sequence context perception optimization. The method can realize high-precision prediction of the drug target, and can be widely applied to the technical field of drug target prediction.
Owner:GUANGDONG INST OF INTELLIGENT SCI & TECH
Nanometer antibody-proximity marker enzyme fusion protein and application thereof
PendingCN119998331AComponent separationPeptide preparation methodsAntiendomysial antibodiesProtein target
The invention belongs to the technical field of biology, and particularly relates to a nano antibody-proximity marker enzyme fusion protein and application thereof. Specifically, the present disclosure provides a fusion protein for proximity labeling wherein the fusion protein is operably linked together by (a) a nanobody and (b) a proximity labeling enzyme; optionally, a peptide linker is also included between the nano antibody and the proximity marker enzyme. The nano antibody-proximity marker enzyme fusion protein disclosed by the invention is obtained through in-vitro expression and purification, target protein is targeted by using an antibody, and the nano antibody-proximity marker enzyme fusion protein does not depend on an overexpression system and has compatibility to various cell types, tissues and clinical fixed samples; proteins with post-translational modification and various organelles, such as membraneless organelles, can be targeted; and the positioning accuracy rate reaches 100%.
Owner:INSTITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES